Did You Know...
...that Kleenex tissue was originally designed to be a gas mask filter? It was developed at the beginning of World War I to replace cotton, which was then in short supply as a surgical dressing.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173135 | Methods for preparing complex multivalent immunogenic conjugates Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction invo... | 05/08/2012 |
| 8137675 | Bont/a peptides and methodsof predicting and reducing immunoresistance to botulinum toxin therapy The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides. ... | 03/20/2012 |
| 8133492 | Pneumococcus polysaccharide-related vaccines This invention provides novel nitrocellulose-based or Hydrogel-based microarrays and methods of making and using them (1) to detect the presence of one or more agents in a sample, (2) to determine the amount of one or more agents in a sample, (3) to determine whethe... | 03/13/2012 |
| 8034353 | Peptide vaccine for inducing the production of anti-amyloid β-peptide antibody An object of the present invention is to provide a peptide vaccine for preventing and/or treating diseases caused by amyloid β-peptide, such as Alzheimer's disease. The present invention solves the above object by providing a peptide vaccine constructed by insertin... | 10/11/2011 |
| 8029798 | Multivalent vaccine composition with mixed carrier The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosid... | 10/04/2011 |
| 8003112 | Meningococcal and pneumococcal conjugate vaccine and method of using same This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated rec... | 08/23/2011 |
| 7862823 | Multivalent vaccine composition with mixed carrier The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosid... | 01/04/2011 |
| 7678379 | epitopes and methods of use thereof The invention provides novel Class I HLA-A2 and Class II HLA-DR4-restricted epitopes and methods for their use in detecting T-cells in peripheral blood specific for infection or latency of mycobacterial infection, including M. tuberculosis and M. leprae | 03/16/2010 |
| 7635484 | BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides. ... | 12/22/2009 |
| 7635483 | Streptococcal C5a peptidase vaccine Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal agai... | 12/22/2009 |
| 7628992 | Modification of clostridial toxins for use as transport proteins A chemical conjugate for treating a nerve cell related disorder is provided. This conjugate includes an active or inactive Clostridial toxin having specificity for a target nerve cell. The toxin is conjugated to a drug or other bioactive molecule without affecting t... | 12/08/2009 |
| 7544361 | Hetero type pentamer recombinant vaccine A heteropentamer composed of a fusion monomer (32) comprising a fusion protein of an antigenic amino acid sequence and an amino acid sequence of a monomer of a mucous membrane-binding protein and a nonfusion monomer (20) of an amino acid sequence of a ... | 06/09/2009 |
| 7531179 | BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides. ... | 05/12/2009 |
| 7510717 | Non-toxic mutants of pathogenic gram-negative bacteria A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a m... | 03/31/2009 |
| 7449189 | Glycoconjugate vaccines for use in immune-compromised populations Staphylococcal and Enterrococcal glycoconjugate vaccines are disclosed for use in preventing or treating bacterial infection in an immune-compromised individual. Such vaccines contain an immunocarrier and a conjugate of a polysaccharide or glycopeptide... | 11/11/2008 |
| 7408044 | Carrier protein having an adjuvant effect The invention relates to an adjuvant product which is intended to improve the activity of a molecule when administered to a host, characterized in that it comprises at least one part of the P40 protein of Klebsiella pneumoniae or a protein having at least 80% homolo... | 08/05/2008 |
| 7384639 | Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to... | 06/10/2008 |
| 7371723 | Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc... | 05/13/2008 |
| 7364740 | Molecular differences between species of the complex Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish betw... | 04/29/2008 |
| 7332173 | Group A streptococcal polysaccharide immunogenic compositions and methods This invention provides a novel immunogenic composition and vaccine, processes for producing them and methods for immunization against infections and disease caused by group A Streptococci. The compositions include group A streptococcal polysaccharide covalently lin... | 02/19/2008 |
| 7329409 | Compositions and methods for treatment of microbial infections The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pa... | 02/12/2008 |
| 7323175 | Immunogenicity of glucan binding protein Immunogenic compositions and subunit vaccines for dental caries are described which comprise peptide subunits of glucan binding protein-B and peptide subunits of glucan binding protein-B in combination with peptide subunits of glucosyltransferase. Methods of provoki... | 01/29/2008 |
| 7316996 | Bisacyloxypropylcysteine conjugates and the use thereof The invention provides lipopeptide conjugates in which a cysteine that is double-substituted by a fatty acid is bonded by means of the carboxyl group to a highly soluble, physiologically compatible and non-immunogenic, polymeric conjugate group. The conjugates exhib... | 01/08/2008 |
| 7285635 | Modified proteins, designer toxins, and methods of making thereof The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositio... | 10/23/2007 |
| 7282580 | Protein molecule useful for inhibition of anthrax toxin The present invention relates to a novel molecule useful for anthrax toxin inhibition in vivo and also provides a method for in vivo inhibition of anthrax toxin action using the new molecule. ... | 10/16/2007 |
| 7279169 | Mucosal DTPa vaccines Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) or E. coli heat labile toxin (LT). Component (b) acts as a muco... | 10/09/2007 |
| 7279162 | Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection The invention describes the identification, making, and isolation of immunoglobulin and antigen useful for preventing, diagnosing, and treating staphylococcal infections. The invention further describes an in vivo animal model useful for testing the efficacy of phar... | 10/09/2007 |
| 7270827 | Multivalent streptococcal vaccine compositions and methods for use Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nu... | 09/18/2007 |
| 7262014 | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g.... | 08/28/2007 |
| 7258863 | Heterologous protection induced by immunization with invaplex vaccine In this application is described a composition, Invaplex, derived from a gram negative bacteria for use in generating an immune response in a subject against one or more heterologous species or strains of gram-negative bacteria. ... | 08/21/2007 |
| 7255867 | Vaccine Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in in... | 08/14/2007 |
| 7247307 | Vaccines against O157 infection This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including... | 07/24/2007 |
| 7235242 | IgA1 protease fragment as carrier peptides The present invention is concerned with a fragment of IgA1-protease having 40 to 200 amino acid residues and comprising at least 40 amino acids of an amino acid sequence as shown in SEQ ID NO:1, beginning with the amino acid in any one of positions 1 to 5 and ending... | 06/26/2007 |
| 7235243 | Immunological combination compositions and methods Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the... | 06/26/2007 |
| 7229622 | Synthetic chimeric fimbrin peptides The present invention provides synthetic chimeric fimbrin peptides which induce an immunogenic response in animals to non-typable Haemophilus influenzae and that do not require tedious purification techniques. The synthetic chimeric fimbrin peptides reduce th... | 06/12/2007 |
| 7226601 | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococca... | 06/05/2007 |
| 7226603 | HBV core antigen particles with multiple immunogenic components attached via peptide ligands This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related struct... | 06/05/2007 |
| 7217791 | Compositions and methods for treating or preventing pneumococcal infection The invention provides polypeptides, polysaccharide-polypeptide conjugates, and expression vectors for treating or preventing pneumococcal infection. The compositions induce an anti-pneumococcal immune response when administered to a mammal. The compositions can be ... | 05/15/2007 |
| 7211411 | Human papilloma virus treatment Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disc... | 05/01/2007 |
| 7201912 | Recombinant immunogenic compositions and methods for protecting against lethal infections from Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis having a variant of recombinant Bacillus anthracis protective antigen (rPA) and a variant of recombinant Bacillus anthracis lethal ... | 04/10/2007 |
